AU;Current Trials
  • Home
  • Clinical Trials
  • Obesity Studies North Auckland

ORCHID Obesity Study

North Auckland

We are looking for adults 18+ who are living with obesity or who are overweight and have at least one weight-related health condition (such as high blood pressure, high cholesterol, or sleep apnoea) to take part in a clinical research study investigating a new once-weekly injectable medication designed to help with weight management.

Description

What to expect

Study details

Ages

18+

Duration

14 clinic visits and 7 virtual visits over 1.5 years

Compensation

Eligible participants will be reimbursed for time and travel costs.

Eligibility Criteria

  • Adults aged 18 years or older
  • BMI ≥30 kg/m² 
  • BMI ≥27 kg/m² with at least one of the following: (hypertension/high cholesterol, dyslipidaemia, high cholesterol, sleep apnoea, or cardiovascular disease)
  • Have a history of at least one unsuccessful weight loss attempt with diet/exercise in the last 6 months 
  • Participants of childbearing potential must use effective contraception and have negative pregnancy tests

Locations

North Auckland

Description

About Obesity

Living with obesity increases the risk of developing other health problems such as high blood pressure, high cholesterol, sleep apnoea, and heart disease. Managing body weight can help lower these risks and improve quality of life. Many people find that lifestyle changes alone are not always enough to achieve or maintain weight loss. Researchers are studying new medications that target appetite and metabolism to help people better manage their weight.

About the Investigational Medication 

KAI-9531 is a new GLP-1/GIP receptor agonist being investigated for its ability to:

  • Help regulate appetite and calorie intake.
  • Promote weight loss.
  • Improve metabolic health markers.

It is given once weekly by injection under the skin. This medication works by acting on specific receptors in the body that help control hunger and food intake. Previous research suggests that GLP-1/GIP receptor agonist medications may be effective for weight management in people without diabetes, and this study will further assess the safety and effectiveness of KAI-9531 over a 76-week period.

What to expect

About The Study

If you are interested in taking part, you will first meet with a study doctor to review your medical history and determine if this study is right for you. If eligible, you will participate for around 18 months, including both clinic and virtual visits. During these visits, we’ll perform general health checks (such as physical exams and blood tests), collect body measurements, and ask questions about your lifestyle and well-being.

You’ll take the study medication, KAI-9531, or a placebo, once a week by injection under the skin (subcutaneous). You will receive training on how to give the injection yourself at home.

This study involves approximately 1,800 participants worldwide and aims to determine whether KAI-9531 can help reduce body weight and improve related health outcomes.

Why Join this Clinical Research Study?

Your participation in this study may help advance medical understanding of new treatments for obesity and overweight-related health conditions. Other reasons to participate include:

  • Regular health monitoring by a dedicated medical team
  • Reimbursement for time and travel costs
  • All study-related care is provided free of charge

 

Your privacy is important, and all personal information will be kept strictly confidential.

Apply now

Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.

Momentum Clinical Research NZ is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. Our Privacy Policy also contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.

Therapeutic AreasClinical TrialsAboutContactCareersNews
ParticipantsSponsors

New Zealand locations

AucklandPukekohe AucklandNorth AucklandWest AucklandWaikatoTaurangaRotoruaPalmerston NorthHutt ValleyKapitiWellingtonNelsonChristchurchDunedin

Australian locations

Fortitude Valley BrisbaneTaringa BrisbaneSunshine MelbourneDarlinghurst SydneySt Leonards Sydney

2026 © Momentum Clinical Research

Privacy Policy